Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus SELENOMETHIONINE SE 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus SELENOMETHIONINE SE 75.
INDIUM IN 111 CHLORIDE vs SELENOMETHIONINE SE 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
None Documented
None Documented
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical